VHL and nonpapillary renal cell carcinoma: Targeting VEGF is developed based on the long-term investigations demonstrating loss of the von Hippel-Lindau (VHL) tumor-suppressor, due to 3p loss [10], mutations [11], and promoter methylation [12], as the common initiating event of ccRCC [13,14].